clariane

2024 Q1 revenue

25 April 2024

Philippe Garin - Chief Financial Officer

In this presentation, and unless otherwise indicated, all changes are stated on a year-on-year basis (2024/2023), and at constant scope and exchange rates.

This presentation may contain forward-looking statements. Such forward-looking statements do not constitute forecasts regarding results or any other performance indicator, but rather trends or targets.

These statements are by their nature subject to risks and uncertainties as described in the Company's Universal Registration Document available on its website (www.clariane.com).

Accordingly, these statements do not necessarily reflect the Company's future performance, which may differ significantly. The Company does not undertake to provide updates of these statements. Further information about Clariane is available on its website (www.clariane.com).

First Quarter key highlights:

Solid business growth in the first quarter of 2024:
Revenue up 7.4%

All regions and business segments contributing to growth

2024 objectives confirmed

Organic revenue growth of over 5% Stable EBITDA in value pre IFRS 16 (pro forma basis)

Refinancing Plan well underway in the first quarter

Well balanced growth between volume and price

Reported and organic +7.4% growth:

Business volumes +€47 million

+3.9%


Price increases +€43 million

+3.5%



Long Term Care occupancy rate







Page 5

Solid growth in all activities, demonstrating a successful diversified portfolio

GROWTH BY ACTIVITY

	_	Q1 2023 Revenue (€m)	Q1 2024 Revenue (€m)	Share of revenue	Reported growth	Organic growth
Long Term Care		759	802	61.5%	5.7%	7.1 %
Specialized care		322	337	25.8%	4.8%	5.1%
Community Care		138	169	12.8%	22.3%	14.4%
Total		1218	1308		7.4%	7.4%

All geographies growing well

GROWTH BY COUNTRY

	Q1 24 Reported growth	Q1 24 Organio growth
France	8.2%	7.0%
Germany	7.6%	7.9%
Benelux	5.7%	8.1%
Italy	3.5%	4.3%
Spain, UK	13.2%	13.6%
Total	7.4 %	7.4 %

France: strong business levels



€m (excluding IFRS 16)	Q1 24
REVENUE	579
REPORTED GROWTH	8.2%
ORGANIC GROWTH	7.0%

- Organic revenue growth in the Long-Term Care segment: +6.4%
 - Price and volume increases
- Specialized Care organic revenue growth of 6.1%.
 - Each sub-segment homecare, mental health and medical and rehabilitation care – achieved significant growth
 - Outpatient and partial hospitalisation activities contributed well to all facilities
- Community Care grew by +25.5% organically, driven by robust demand for services of Ages & Vie and Petits-fils



Germany: price increases have not yet fully offset cost increases



€m (excluding IFRS 16)	Q1 24
REVENUE	304
REPORTED GROWTH	7.6%
ORGANIC GROWTH	7.9%

Revenue rose sharply, driven mainly by price increases negotiated in 2023 with local authorities

- Long-Term Care posted organic growth of +7.2%, supported by price rises and an occupancy rate that rose to 88.8% in Q1 24
- Revenue in Community Care grew by +9.2% on an organic basis



Benelux

€m (excluding IFRS 16)	Q1 24
REVENUE	191
REPORTED GROWTH	5.7%
ORGANIC GROWTH	8.1%



Revenue totalled €154 million, up 5.7% on an organic basis.

- Long-Term Care posted organic growth of +4.9%, with occupancy rate that rose from 89.5% in Q1 23 to 91.6% in Q1 24, and by regular price rises
- **Community Care** over 7% of the Group's revenue in Benelux achieved rapid organic growth of 16.7%
- The Group's three Dutch business segments achieved firm growth throughout the period
 - **Long-Term Care** revenue rose by 20.5%, supported by rapid ramp-up of recently completed greenfield facilities in favourable market conditions
 - Stable revenue in **Specialized Care** just over 2% of revenue in the Netherlands
 - **Community Care** around 15% of the Group's revenue in the Netherlands achieved organic revenue growth of 18.1%



Italy & Spain/United Kingdom

ITALY

€m (excluding IFRS 16)	Q1 24
REVENUE	158
REPORTED GROWTH	3.5%
ORGANIC GROWTH	4.3%

SPAIN/UNITED KINGDOM

€m (excluding IFRS 16)	Q1 24
REVENUE	76
REPORTED GROWTH	13.2%
ORGANIC GROWTH	13.6%



- **Long-term care** revenue grew by 7.9% on an organic basis, supported by an occupancy rate of 95.6% versus 92.2% in Q1 2023
- Revenue in Specialized Care -around 46% of the total in Italy- was stable
- **Community Care** which makes up around 7% of the Group's revenue in Italy grew organically by +7.9%



In Spain, revenue totalled €59 million, up 11.0% on an organic basis

- Long-Term Care –or around 19% of revenue in Spain rose by 9.1% on an organic basis supported by an occupancy rate of 88.5% versus 83.8% in the first quarter of 2023, and by a slight increase in prices
- Specialized Care revenue grew 8.5% on an organic basis. Grupo 5 no longer had a significant impact on the scope of consolidation since it was integrated in Q1 2023
- Community Care –only accounts for around 4% of the Group's revenue in Spain – remained highly volatile



- Revenue totalled €17 million, up 23.7% on an organic basis
- Disposal was achieved on 9 April 2024,



€1.5 billion Refinancing Plan well on track

Achieved

On going

2 Real Estate Equity Partnerships

€230m

End of 2023 as expected

Real Estate Debt Bridge

€200m

End of 2023 as expected

Disposals as of today

€268m

27% of the €1bn target

Capital Increase

€300m

- AMF exemption granted*
- EGM approvals obtained
- Antitrust filed
- Capital raise expected:
 Q2 or Q3 2024



Further disposals according to plan

~€800m


Targeted processes underway:

Of which Benelux

Debt reduction underway with the UK platform disposal Objective of a leverage ratio below 3x, with a LTV @55%, end of 2025



Outlook 2024



These objectives will be adjusted to take into account changes in scope resulting from the disposal plan target

Key focus for 2024

Deploying « At your side » corporate project

Leveraging existing capacities to address growing inpatient and outpatient care demand Strengthening core capabilities: Quality & Operating model, HR, Digital Inclusive governance to ensure trust

Executing the refinancing plan

8

Driving FCF generation

Optimizing WCR Limiting growth investments to c. €200m on average (24-25)

